Whether patients with myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) benefit from pretransplant cytoreductive therapy remains controversial. Our study compared the outcomes of upfront those in who received and dropped out due to therapy-related adverse effects. Patients MDS-EB-1 or MDS-EB-2 were enrolled divided into three groups based o...
